SCHEMBL5876273

SCHEMBL5876273

Nc1n[nH]c2c1C=CC(c1ccccc1)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.36
LTK P29376 2/20 0.36
KDR P35968 2/20 0.36
MAPK8 P45983 2/20 0.36
CSNK1A1 P48729 2/20 0.36
LIMK1 P53667 2/20 0.36
CDK5 Q00535 2/20 0.36
CLK4 Q9HAZ1 2/20 0.36
DYRK1B Q9Y463 2/20 0.36
MAP4K4 O95819 1/20 0.36
FGFR1 P11362 1/20 0.36
PDGFRA P16234 1/20 0.36
ACVR1 Q04771 1/20 0.36
TNK2 Q07912 1/20 0.36
AURKB Q96GD4 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
PIM1 P11309 1/20 0.36
FLT3 P36888 1/20 0.36
AKT2 P31751 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876644 0.82 MAPK10 (0.46) KDRNPSR1PIM1FLT3HCAR2
SCHEMBL5877349 0.78 ERBB2 (0.36) CSF1RLTKKDRMAPK8CSNK1A1
SCHEMBL5877114 0.77 MKNK1 (0.40) MAPK1PIM1FLT3HCAR2LMNA
SCHEMBL5876901 0.75 LRRK2 (0.40) PIM1HCAR2LRRK2LMNAMAPK10
SCHEMBL5877175 0.74 IDO1 (0.45) MAPK1PIM1KMT2ALRRK2LMNA
SCHEMBL5876817 0.74 KDM4E (0.39) KDRMAPK1KMT2AHCAR2LMNA
SCHEMBL5878102 0.74 IDO1 (0.42) CSF1RLTKKDRMAPK8CSNK1A1
SCHEMBL5875946 0.74 ADORA2A (0.38) KDRHCAR2LMNAMAPK10HTR7
SCHEMBL5875924 0.74 HCAR2 (0.38) PIM1FLT3HCAR2LMNAMAPK10
SCHEMBL5878112 0.74 HCAR2 (0.44) KMT2AHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed
EP-1414805-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY Aventis Pharma S.A. (FR) 2004-05-06 EP disclosed
WO-2003011833-A1 INDAZOLE OR INDOLE DERIVATIVES, THEIR USE IN HUMAN MEDICINE AND MORE PARTICULARLY IN CANCEROLOGY AVENTIS PHARMA S.A. (FR) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT CSF1R 680/4885LTK 1171/4885KDR 2511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.